China SMid Insurance: China Taiping: Niche robot insurance as a SMid-cap catalyst

Research evidence excerpt

China SMid Insurance: China Taiping: Niche robot insurance as a SMid-cap catalyst

Asia Pacific Equity Research

22 June 2026

China SMid Insurance

China Taiping: Niche robot insurance as a SMid-cap

catalyst

Unlike China large-cap insurers, which are primarily driven by earnings Insurance

consensus revisions, life sales growth expectations, and attractive 4%-6% AC Dan Wang

dividend yields, SMid-cap insurers trade on different growth narratives. ZhongAn

(86-21) 6106-6349

Online P&C is a clear example. It has not paid a dividend since its 2017 IPO, dan.wang@jpmorgan.com

instead reinvesting excess capital into organic growth. Its share price has been SAC Registration Number: S1730524080001

supported mainly by differentiated product innovation, including shipping-return J.P. Morgan Securities (China) Company

and pet insurance. This is why niche-market development matters for China’s Limited

SMid insurers. We estimate that China’s humanoid robot insurance market will MW Kim

expand from Rmb0.01B in 2025 to Rmb1.17B by 2030. This can create a tangible (852) 2800-8517

share-price catalyst for SMid players. China Taiping is uniquely positioned for mw.kim@jpmorgan.com

this opportunity. The stock looks inexpensive, trading at an FY27E P/E of 5x with J.P. Morgan Securities (Asia Pacific) Limited/

a 4% dividend yield. We like China Taiping on this theme given its integrated J.P. Morgan Broking (Hong Kong) Limited

P&C and reinsurance capacity to underwrite high-value robot-related risks, as

well as its central SOE credentials, which should help it secure bulk insurance

orders from national industrial parks.

• Humanoid robots and insurers. Rapid commercial deployment of humanoid

robots is creating demand for dedicated insurance products, as conventional